What requirement is stated for FDA-regulated drug studies regarding ICH E6 compliance?

The requirement for FDA-regulated drug studies regarding ICH E6 compliance is that compliance is mandatory for all studies. The International Council for Harmonisation (ICH) guidelines, specifically E6, provide a framework for good clinical practice (GCP) and are designed to ensure the integrity of research data, the protection of study participants, and the reliability of clinical trial outcomes. The FDA recognizes these guidelines, making adherence to them essential for all clinical trials submitted for regulatory review.

ICH E6 guidelines set forth standards that govern the conduct of clinical trials across multiple regions and ensure that the data produced is credible and accurate. Therefore, compliance is not optional, nor is it limited to just specific types of trials or geographic locations. All clinical trials that involve drug applications for FDA consideration need to adhere to ICH E6 standards, which is crucial for maintaining the safety and efficacy of pharmaceuticals being developed and tested.